INOVIO Pharmaceuticals

Company snapshot

INOVIO is a clinical stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. Our mission: deliver on the promise of DNA medicine for patients around the world. For more information, visit www.inovio.com.

• 46 active pipeline program(s) linked via ClinicalTrials.gov.
• 75 US patent(s) indexed to this assignee profile.
• 46 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for INOVIO Pharmaceuticals. Not investment advice.

• Peer + 0 momentum

  United Therapeutics Europe

  TA overlap score 40

• Peer + 0 momentum

  First People's Hospital

  TA overlap score 40

• Peer + 0 momentum

  Atea Pharmaceuticals

  TA overlap score 27.4

• Peer + 0 momentum

  Oncolytics Biotech

  TA overlap score 24.6

• Peer + 0 momentum

  Peking University Biologics

  TA overlap score 23

• Peer + 0 momentum

  Advanced Accelerator Applications

  TA overlap score 22.4

• Peer + 0 momentum

  Barinthus Biotherapeutics

  TA overlap score 21.8

Recent activity

Latest pipeline, patent, and corporate events for INOVIO Pharmaceuticals.

1. Jun 8, 2026 Clinical update

   INO-1800 — Phase 1

2. Jun 8, 2026 Clinical update

   2mg INO-5150 and electroporation device CELLECTRA®-5P — Phase 1

3. Jun 5, 2026 Clinical update

   VGX-3100 — Phase 2

4. Jun 5, 2026 Clinical update

   VGX 3100 — Phase 2

5. Jun 5, 2026 Clinical update

   p.DOM-WT1-37 DNA Vaccine and p.DOM-WT1-126 DNA Vaccine — Phase 2

View all clinical trial activity →

• What is INOVIO Pharmaceuticals?

  INOVIO Pharmaceuticals is a pharma organization headquartered in Plymouth Meeting, USA. It trades on NYSE under ticker INO. Primary therapeutic focus areas include Anal Neoplasm, Lassa Fever, Prostate Cancer, Chronic Hepatitis C Virus Infection, Chronic Hepatitis C. NovaPharmaNew

• Is INOVIO Pharmaceuticals publicly traded?

  Yes. INOVIO Pharmaceuticals is listed with ticker INO on NYSE per SEC EDGAR records linked on this profile.

• What drugs does INOVIO Pharmaceuticals develop or market?

  We link 8 drug profile(s) where INOVIO Pharmaceuticals is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/inovio-pharmaceuticals-inc#company-drugs.

• What are the latest developments for INOVIO Pharmaceuticals?

  In the last 12 months our linked public records show 46 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does INOVIO Pharmaceuticals focus on?

  INOVIO Pharmaceuticals focuses on Anal Neoplasm, Lassa Fever, Prostate Cancer based on our analysis of their pipeline programs and drug development activities.